ACAD

AI Memo

ACADIA

As of 2026-10-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

RADIANT Phase 2 miss resets the remlifanserin thesis • 2026-09-24

Base target: $18 / p=45% prob

Biggest risk

A missed primary endpoint, weak 30 mg results and the need to amend Phase 3 reduce confidence in remlifanserin. Secondary coverage reports post-readout target cuts, including Needham to $35 from $41 and Deutsche Bank to $31 from $38; these are reported analyst actions, not independently verified revisions. [#8-K-2026-09-24]

Invalidation

Break below $12 or thesis failure.

What would change my mind?

DAYBUE and NUPLAZID growth may support the business while the 60 mg remlifanserin signal is tested further. The Q2 release reported $956 million of cash, equivalents and investments at June 30. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-14

Base target

$18

p=45%

Bull target

$26

p=20%

Bear target

$12

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

DAYBUE and NUPLAZID execution against 2026 guidance
DAYBUE and NUPLAZID growth may support the business while the 60 mg remlifanserin signal is tested further.
The Q2 release reported $956 million of cash, equivalents and investments at June 30.

BearKey bullets

Commercial growth must sustain raised guidance while R&D and selling expenses continue; Q2 R&D was $82 million and SG&A was $160 million.
[#SEC-8K-2026-08-04]
Detailed data and subsequent Phase 3 outcomes remain uncertain; the packet provides no confirmed regulatory decision date.

WatchKey bullets

RADIANT Phase 2 miss resets the remlifanserin thesis

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $18 (p=45%)

Target spread vs base: +44% / -33%

Scenario probabilities

Bull Target: $26 (p=20%)Base Target: $18 (p=45%)Bear Target: $12 (p=35%)

Commentary

September coverage was negative following the RADIANT miss, and stored secondary reporting describes analyst target cuts. The $18.62 October 13 anchor is about 16% below a reported $22.18 September 25 close, though that later decline cannot be attributed solely to the trial. The reported analyst revisions have not been independently confirmed. Social, options, short-interest and employee measurements are unavailable; zeros above denote missing data, not neutral readings.

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

DAYBUE and NUPLAZID execution against 2026 guidance

Scenarios

Bull Target (Scenario probability)

$26 / p=20% prob

Base Target (Scenario probability)

$18 / p=45% prob

Bear Target (Scenario probability)

$12 / p=35% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-24
RADIANT Phase 2 miss resets the remlifanserin thesis
The 60 mg dose missed the primary endpoint (p=0.0603), while a key secondary endpoint was nominally significant (p=0.0077). Acadia plans to continue two Phase 3 studies but remove the 30 mg arm. The primary-endpoint miss remains the dominant risk despite the secondary signal. [#8-K-2026-09-24]
Prob 100.00% • Move -8.00% • Priced-in 85.00%
EVENT2026-11-19
Detailed RADIANT results at CTAD
Acadia plans to present detailed efficacy and safety results at CTAD on November 16–19. The presentation may clarify the 60 mg signal and Phase 3 amendments, but cannot erase the Phase 2 primary-endpoint miss. [#8-K-2026-09-24]
Prob 85.00% • Move 7.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

DAYBUE and NUPLAZID execution against 2026 guidance
2026-12-31
Q2 DAYBUE sales rose 30% year over year to $125 million, while NUPLAZID sales were $183 million. Acadia raised 2026 revenue guidance to $1.24–$1.30 billion. Sustained uptake could cushion pipeline weakness; a guidance miss would undermine that support. [#SEC-8K-2026-08-04]
Prob 60% • Move 9% • Priced-in 60%

Risks

Commercial growth must sustain raised guidance while R&D and selling expenses continue; Q2 R&D was $82 million and SG&A was $160 million. [#SEC-8K-2026-08-04]
Detailed data and subsequent Phase 3 outcomes remain uncertain; the packet provides no confirmed regulatory decision date.
The 30 mg arm showed minimal improvement and is being removed from Phase 3, creating protocol and execution risk. [#8-K-2026-09-24]
The 60 mg RADIANT arm missed its prespecified primary endpoint; nominal secondary significance does not establish Phase 3 success. [#8-K-2026-09-24]

Peers

Symbol	Summary
ARQT	Similar-market-cap commercial biopharma comparator, but its dermatology focus makes it a loose operating peer rather than a direct neuroscience valuation benchmark.
IDYA	Similar-market-cap biotechnology comparator, but its pipeline focus differs substantially from Acadia's commercial neuroscience portfolio; valuation read-through is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

ARQT

Similar-market-cap commercial biopharma comparator, but its dermatology focus makes it a loose operating peer rather than a direct neuroscience valuation benchmark.

IDYA

Similar-market-cap biotechnology comparator, but its pipeline focus differs substantially from Acadia's commercial neuroscience portfolio; valuation read-through is limited.